Correction: Exacerbations of chronic obstructive pulmonary disease: When are antibiotics indicated? A systematic review [Respiratory Research, 8, (2007) (30)] doi: 10.1186/1465-9921-8-30

Milo A. Puhan, Daniela Vollenweider, Tsogyal Latshang, Johann Steurer, Claudia Steurer-Stey

Research output: Contribution to journalComment/debate

Abstract

Since publication of our article [1], we have been made aware of an error in our article. We have transposed the proportion of patients with treatment failure in the antibiotic and placebo groups of one trial [2]. 19 out of 57 patients experienced a treatment failure compared to 28 out of 59 patients in the placebo group (odds ratio 0.55 (0.26-1.17). In the results section of the abstract the sentences "For the effects of antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 82%). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.016): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 1.09, 95% CI 0.75-1.59, I2 = 18%)" the text should read: "For the effects of antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 75%). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.038): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 0.81, 95% CI 0.55-1.18, I2 = 13%)." In the results section, following the subheading "Effects of antibiotics" the second paragraph "Figure 2 shows that the effects of antibiotics were very heterogeneous across trials (I2 = 82%). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.55), definition of outcomes (p = 0.20), length of follow-up (p = 0.38) and study quality (p = 0.92) did not explain heterogeneity." should read "Figure 2 shows that the effects of antibiotics were very heterogeneous across trials (I2 = 75%). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.59), definition of outcomes (p = 0.06), length of follow-up (p = 0.85) and study quality (p = 0.42) did not explain heterogeneity." In the results section, following the subheading "Effects of antibiotics" the fourth paragraph "When we did the metaanalysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.016). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 1.09, 95% CI 0.75-1.59, I2 = 18%). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.55, 95% CI 0.41-0.74, with a number-needed to treat of 9, 95% CI 6-16) but there was a large amount of heterogeneity (I2 = 87%)." should read "When we did the meta-analysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.038). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 0.81, 95% CI 0.55-1.18, I2 = 1 three%). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.45, 95% CI 0.34-0.61, with a number-needed to treat of 9, 95% CI 7-12) but there was a large amount of heterogeneity (I2 = 83%)." The corrected versions of Figures two and three are given here- see figures 1 and 2. We apologize for any inconvenience or confusion that this may have caused.

Original languageEnglish (US)
Article number81
JournalRespiratory Research
Volume9
Issue number1
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Chronic Obstructive Pulmonary Disease
Anti-Bacterial Agents
Treatment Failure
Research
fexofenadine
Meta-Analysis
Numbers Needed To Treat
Odds Ratio
Outpatients
Placebos
Regression Analysis
Publications

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Correction : Exacerbations of chronic obstructive pulmonary disease: When are antibiotics indicated? A systematic review [Respiratory Research, 8, (2007) (30)] doi: 10.1186/1465-9921-8-30. / Puhan, Milo A.; Vollenweider, Daniela; Latshang, Tsogyal; Steurer, Johann; Steurer-Stey, Claudia.

In: Respiratory Research, Vol. 9, No. 1, 81, 2008.

Research output: Contribution to journalComment/debate

@article{a5bf0d0b0f994a68b766c4733c6537cb,
title = "Correction: Exacerbations of chronic obstructive pulmonary disease: When are antibiotics indicated? A systematic review [Respiratory Research, 8, (2007) (30)] doi: 10.1186/1465-9921-8-30",
abstract = "Since publication of our article [1], we have been made aware of an error in our article. We have transposed the proportion of patients with treatment failure in the antibiotic and placebo groups of one trial [2]. 19 out of 57 patients experienced a treatment failure compared to 28 out of 59 patients in the placebo group (odds ratio 0.55 (0.26-1.17). In the results section of the abstract the sentences {"}For the effects of antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 82{\%}). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.016): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 1.09, 95{\%} CI 0.75-1.59, I2 = 18{\%}){"} the text should read: {"}For the effects of antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 75{\%}). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.038): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 0.81, 95{\%} CI 0.55-1.18, I2 = 13{\%}).{"} In the results section, following the subheading {"}Effects of antibiotics{"} the second paragraph {"}Figure 2 shows that the effects of antibiotics were very heterogeneous across trials (I2 = 82{\%}). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.55), definition of outcomes (p = 0.20), length of follow-up (p = 0.38) and study quality (p = 0.92) did not explain heterogeneity.{"} should read {"}Figure 2 shows that the effects of antibiotics were very heterogeneous across trials (I2 = 75{\%}). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.59), definition of outcomes (p = 0.06), length of follow-up (p = 0.85) and study quality (p = 0.42) did not explain heterogeneity.{"} In the results section, following the subheading {"}Effects of antibiotics{"} the fourth paragraph {"}When we did the metaanalysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.016). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 1.09, 95{\%} CI 0.75-1.59, I2 = 18{\%}). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.55, 95{\%} CI 0.41-0.74, with a number-needed to treat of 9, 95{\%} CI 6-16) but there was a large amount of heterogeneity (I2 = 87{\%}).{"} should read {"}When we did the meta-analysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.038). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 0.81, 95{\%} CI 0.55-1.18, I2 = 1 three{\%}). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.45, 95{\%} CI 0.34-0.61, with a number-needed to treat of 9, 95{\%} CI 7-12) but there was a large amount of heterogeneity (I2 = 83{\%}).{"} The corrected versions of Figures two and three are given here- see figures 1 and 2. We apologize for any inconvenience or confusion that this may have caused.",
author = "Puhan, {Milo A.} and Daniela Vollenweider and Tsogyal Latshang and Johann Steurer and Claudia Steurer-Stey",
year = "2008",
doi = "10.1186/1465-9921-9-81",
language = "English (US)",
volume = "9",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Correction

T2 - Exacerbations of chronic obstructive pulmonary disease: When are antibiotics indicated? A systematic review [Respiratory Research, 8, (2007) (30)] doi: 10.1186/1465-9921-8-30

AU - Puhan, Milo A.

AU - Vollenweider, Daniela

AU - Latshang, Tsogyal

AU - Steurer, Johann

AU - Steurer-Stey, Claudia

PY - 2008

Y1 - 2008

N2 - Since publication of our article [1], we have been made aware of an error in our article. We have transposed the proportion of patients with treatment failure in the antibiotic and placebo groups of one trial [2]. 19 out of 57 patients experienced a treatment failure compared to 28 out of 59 patients in the placebo group (odds ratio 0.55 (0.26-1.17). In the results section of the abstract the sentences "For the effects of antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 82%). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.016): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 1.09, 95% CI 0.75-1.59, I2 = 18%)" the text should read: "For the effects of antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 75%). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.038): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 0.81, 95% CI 0.55-1.18, I2 = 13%)." In the results section, following the subheading "Effects of antibiotics" the second paragraph "Figure 2 shows that the effects of antibiotics were very heterogeneous across trials (I2 = 82%). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.55), definition of outcomes (p = 0.20), length of follow-up (p = 0.38) and study quality (p = 0.92) did not explain heterogeneity." should read "Figure 2 shows that the effects of antibiotics were very heterogeneous across trials (I2 = 75%). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.59), definition of outcomes (p = 0.06), length of follow-up (p = 0.85) and study quality (p = 0.42) did not explain heterogeneity." In the results section, following the subheading "Effects of antibiotics" the fourth paragraph "When we did the metaanalysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.016). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 1.09, 95% CI 0.75-1.59, I2 = 18%). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.55, 95% CI 0.41-0.74, with a number-needed to treat of 9, 95% CI 6-16) but there was a large amount of heterogeneity (I2 = 87%)." should read "When we did the meta-analysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.038). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 0.81, 95% CI 0.55-1.18, I2 = 1 three%). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.45, 95% CI 0.34-0.61, with a number-needed to treat of 9, 95% CI 7-12) but there was a large amount of heterogeneity (I2 = 83%)." The corrected versions of Figures two and three are given here- see figures 1 and 2. We apologize for any inconvenience or confusion that this may have caused.

AB - Since publication of our article [1], we have been made aware of an error in our article. We have transposed the proportion of patients with treatment failure in the antibiotic and placebo groups of one trial [2]. 19 out of 57 patients experienced a treatment failure compared to 28 out of 59 patients in the placebo group (odds ratio 0.55 (0.26-1.17). In the results section of the abstract the sentences "For the effects of antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 82%). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.016): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 1.09, 95% CI 0.75-1.59, I2 = 18%)" the text should read: "For the effects of antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 75%). Meta-regression revealed severity of exacerbation as significant explanation for this heterogeneity (p = 0.038): Antibiotics did not reduce treatment failures in outpatients with mild to moderate exacerbations (pooled odds ratio 0.81, 95% CI 0.55-1.18, I2 = 13%)." In the results section, following the subheading "Effects of antibiotics" the second paragraph "Figure 2 shows that the effects of antibiotics were very heterogeneous across trials (I2 = 82%). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.55), definition of outcomes (p = 0.20), length of follow-up (p = 0.38) and study quality (p = 0.92) did not explain heterogeneity." should read "Figure 2 shows that the effects of antibiotics were very heterogeneous across trials (I2 = 75%). When we explored predefined sources of heterogeneity in meta-regression analyses we found that generation of antibiotic (p = 0.59), definition of outcomes (p = 0.06), length of follow-up (p = 0.85) and study quality (p = 0.42) did not explain heterogeneity." In the results section, following the subheading "Effects of antibiotics" the fourth paragraph "When we did the metaanalysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.016). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 1.09, 95% CI 0.75-1.59, I2 = 18%). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.55, 95% CI 0.41-0.74, with a number-needed to treat of 9, 95% CI 6-16) but there was a large amount of heterogeneity (I2 = 87%)." should read "When we did the meta-analysis without this trial, we found that severity of exacerbations was associated significantly with treatment effects (p = 0.038). Figure three shows the pooled results separately for trials including patients with mild to moderate exacerbations and patients with severe exacerbations. For mild to moderate exacerbations, antibiotics did not significantly reduce the risk for treatment failure (OR 0.81, 95% CI 0.55-1.18, I2 = 1 three%). When the Allegra trial [25] was included in the meta-analysis the pooled estimate favoured antibiotics (OR 0.45, 95% CI 0.34-0.61, with a number-needed to treat of 9, 95% CI 7-12) but there was a large amount of heterogeneity (I2 = 83%)." The corrected versions of Figures two and three are given here- see figures 1 and 2. We apologize for any inconvenience or confusion that this may have caused.

UR - http://www.scopus.com/inward/record.url?scp=84991817978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991817978&partnerID=8YFLogxK

U2 - 10.1186/1465-9921-9-81

DO - 10.1186/1465-9921-9-81

M3 - Comment/debate

AN - SCOPUS:84991817978

VL - 9

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

IS - 1

M1 - 81

ER -